New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Open Access
- 13 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Experimental & Molecular Medicine
- Vol. 52 (4), 556-568
- https://doi.org/10.1038/s12276-020-0418-9
Abstract
Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated with Alzheimer’s disease (AD), i.e., amyloid-β (Aβ) and tau protein, are widely regarded as useful diagnostic biomarkers. However, a lack of biomarkers for monitoring the treatment response and indexing clinical severity has proven to be problematic in drug trials targeting Aβ. Therefore, new biomarkers are needed to track non-Aβ and non-tau pathology. Many proteins involved in the pathophysiological progression of AD have shown promise as new biomarkers. Neurodegeneration- and synapse-related biomarkers in CSF (e.g., neurofilament light polypeptide [NFL], neurogranin, and visinin-like protein 1) and blood (e.g., NFL) aid prediction of AD progress, as well as early diagnosis. Neuroinflammation, lipid dysmetabolism, and impaired protein clearance are considered important components of AD pathophysiology. Inflammation-related proteins in the CSF, such as progranulin, intercellular adhesion molecule 1, and chitinase-3-like protein 1 (YKL-40), are useful for the early detection of AD and can represent clinical severity. Several lipid metabolism-associated biomarkers and protein clearance-linked markers have also been suggested as candidate AD biomarkers. Combinations of subsets of new biomarkers enhance their utility in terms of broadly characterizing AD-associated pathological changes, thereby facilitating precise selection of susceptible patients and comprehensive monitoring of the treatment response. This approach could facilitate the development of effective treatments for AD.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018R1A2B6009439, NRF-2019R1A5A2026045, NRF-2018M3C7A1056293)
This publication has 99 references indexed in Scilit:
- Elevated Osteopontin Levels in Mild Cognitive Impairment and Alzheimer’s DiseaseMediators of Inflammation, 2013
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's DiseaseThe New England Journal of Medicine, 2012
- Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2012
- Neuropathological Alterations in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer diseaseAnnals of Neurology, 2011
- Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cellsCell Death & Differentiation, 2011
- In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseasesJournal of Neuroinflammation, 2010
- Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake CycleScience, 2009
- The role of osteopontin in inflammatory processesJournal of Cell Communication and Signaling, 2009
- Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survivalThe Journal of cell biology, 2008